ICD-10 E88.3
Billable / Specific MCCTumor lysis syndrome
About ICD-10-CM E88.3
ICD-10-CM code E88.3 represents Tumor lysis syndrome. This is a billable/specific code in the Endocrine, Nutritional, and Metabolic chapter (block E88). The 2026 edition of ICD-10-CM E88.3 became effective on October 1, 2025.
Coding Tips for E88.3
Specialist guidance from the PayerReady Medical Coding Team. Specificity warnings, HCC capture rules, sequencing notes.
E88.3 is designated MCC for MS-DRG grouping. On inpatient claims, this code can shift the DRG to the with-MCC variant when documented as a present-on-admission secondary diagnosis. Hospital CDI programs flag MCC opportunities during chart review. Failure to capture this code may leave 30 to 80 percent of the inpatient stay revenue unrealized.
Inclusion Terms / Approximate Synonyms
Clinical terms and conditions classified under E88.3. Per CMS ICD-10-CM Tabular 2026.
- Tumor lysis syndrome (spontaneous)
- Tumor lysis syndrome following antineoplastic drug chemotherapy
Use Additional Code
When coding E88.3, also report these additional codes when applicable.
- code for adverse effect, if applicable, to identify drug (T45.1X5)
Inpatient DRG Impact, MCC
codes Tumor lysis syndrome. As a Major Complication/Comorbidity (MCC), this can shift the DRG assignment to a higher-weighted category, substantial reimbursement impact.
Medicare LCD Coverage for E88.3
Local Coverage Determinations (LCDs) from CMS MACs that list E88.3 as a covered diagnosis.
Showing top 10 of 79 total . Click a CPT for full coverage scope.
Commercial Payer Coverage
Coverage policies from major commercial payers referencing E88.3.
3 Medicare
CPT Codes Commonly Billed with E88.3
Procedures frequently paired with this diagnosis based on PayerReady's Dx↔Px linkage data.
We don't have CPT pairings indexed for this specific code yet. Use the CPT search above to find common procedures, or check your payer's published medical policy for code-specific guidance.
Convert E88.3 to ICD-9-CM
Per CMS General Equivalence Mappings (GEMs), useful for legacy data review and historical claim analysis.
| ICD-10 | ICD-9 | Mapping Flags |
|---|---|---|
| E88.3 | 27788 | 00000 |
Flags format (5 digits): Approximate · No Map · Combination · Scenario · Choice List. Source: CMS 2017 GEMs (final version).
Codes Adjacent To E88.3
Other codes in section E70-E88 (Metabolic disorders).
ICD-10 E88.3, Billing FAQ
Is ICD-10 code E88.3 billable? +
Yes, E88.3 is a billable ICD-10-CM code that can appear as a primary or secondary diagnosis on claims.
What other names or terms map to E88.3? +
ICD-10 E88.3 includes: Tumor lysis syndrome (spontaneous); Tumor lysis syndrome following antineoplastic drug chemotherapy.
Is E88.3 a CC or MCC for inpatient DRG? +
Yes, this code is designated as MCC. Documenting as a secondary diagnosis on inpatient claims can shift the DRG to a higher-weighted category.
What ICD-9 codes does E88.3 map to? +
Per CMS GEMs, E88.3 maps to ICD-9 codes: 27788. Useful for legacy data review and historical claim analysis.
Get the full PayerReady toolkit
Free access to CPT/ICD-10 lookup, denial appeals, fee comparator, and claim auditing with credentialing enrollment.
Start free →Run this code through our claim audit tool
Check NCCI bundling, MUE limits, and modifier logic before submission.
Try the auditor →Did this page help?
Quick signal so we know what to improve.
If you want a code reference page that doesn't exist yet, email coding@payerready.com.
Tell us what's missing or wrong: coding@payerready.com. We respond within 5 business days.
Reviewed by the PayerReady Medical Coding Team
Verified against the CMS 2026 code set on May 31, 2026.
Powered by 11K CPT · 98K ICD-10 · 860K MPFS rates · 4.5M NCCI edits · 9.5M NPIs. Our data methodology · About our coding team